Federal Register / Vol. 79, No. 237 / Wednesday, December 10, 2014 / Notices 73279 

DATES: Nominations should be sent to 

the web address specified below and 

must be received by January 9, 2015. 

ADDRESSES: Applications should be 

submitted electronically to 

noaa.sab.newmembers@noaa.gov. 

FOR FURTHER INFORMATION CONTACT: Dr. 

Cynthia Decker, Executive Director, 

Science Advisory Board, NOAA, Rm. 

11230, 1315 East-West Highway, Silver 

Spring, Maryland 20910. (Phone: 301– 

734–1156, Fax: 301–713–1459, Email: 

Cynthia.Decker@noaa.gov); or visit the 

NOAA SAB Web site at http://

www.sab.noaa.gov. 

SUPPLEMENTARY INFORMATION: 

Individuals are sought with expertise in 

meteorology, operational weather and 

water forecasting, water resources and 

climate. Individuals with expertise in 

the physical sciences, social sciences, 

and communications in these fields will 

all be given consideration. 

Dated: December 5, 2014. 

Jason Donaldson, 

Chief Financial Officer, Office of Oceanic and 

Atmospheric Research, National Oceanic and 

Atmospheric Administration. 

[FR Doc. 2014–28939 Filed 12–9–14; 8:45 am] 

BILLING CODE 3510–KD–P 

DEPARTMENT OF COMMERCE 

Patent and Trademark Office 

[Docket No. PTO–P–2014–0065] 

Grant of Interim Extension of the Term 

of U.S. Patent No. 5,693,323; 

Recombinant Humanized Monoclonal 

Antibody (IgG1, Kappa)-Mepolizumab 

AGENCY: United States Patent and 

Trademark Office, Commerce. 

ACTION: Notice of interim patent term 

extension. 

SUMMARY: The United States Patent and 

Trademark Office has issued an order 

granting interim extension under 35 

U.S.C. 156(d)(5) for a one-year interim 

extension of the term of U.S. Patent No. 

5,693,323. 

FOR FURTHER INFORMATION CONTACT: 

Mary C. Till by telephone at (571) 272– 

7755; by mail marked to her attention 

and addressed to the Commissioner for 

Patents, Mail Stop Hatch-Waxman PTE, 

P.O. Box 1450, Alexandria, VA 22313– 

1450; by fax marked to her attention at 

(571) 273–7755; or by email to 

Mary.Till@uspto.gov. 

SUPPLEMENTARY INFORMATION: Section 

156 of Title 35, United States Code, 

generally provides that the term of a 

patent may be extended for a period of 

up to five years if the patent claims a 

product, or a method of making or using 

a product, that has been subject to 

certain defined regulatory review, and 

that the patent may be extended for 

interim periods of up to one year if the 

regulatory review is anticipated to 

extend beyond the expiration date of the 

patent. 

On November 24, 2014, 

GlaxoSmithKline LLC and SmithKline 

Beecham Limited timely filed an 

application under 35 U.S.C. 156(d)(5) 

for an interim extension of the term of 

U.S. Patent No. 5,693,323. The patent 

claims the human biological product 

Mepolizumab, a recombinant 

humanized monoclonal antibody (IgG1, 

Kappa). The application indicates that a 

Biologics License Application, BLA 

125526, for the human biological 

product has been filed, and is currently 

undergoing regulatory review before the 

Food and Drug Administration for 

permission to market or use the product 

commercially. 

Review of the application indicates 

that, except for permission to market or 

use the product commercially, the 

subject patent would be eligible for an 

extension of the patent term under 35 

U.S.C. 156, and that the patent should 

be extended for one year as required by 

35 U.S.C. 156(d)(5)(B). Because it is 

apparent that the regulatory review 

period will continue beyond the original 

expiration date of the patent, December 

23, 2014, interim extension of the patent 

term under 35 U.S.C. 156(d)(5) is 

appropriate. 

An interim extension under 35 U.S.C. 

156(d)(5) of the term of U.S. Patent No. 

5,693,323 is granted for a period of one 

year from the original expiration date of 

the patent. 

Dated: December 5, 2014. 

Andrew Hirshfeld, 

Deputy Commissioner for Patent Examination 

Policy, United States Patent and Trademark 

Office. 

[FR Doc. 2014–28966 Filed 12–9–14; 8:45 am] 

BILLING CODE 3510–16–P 

DEPARTMENT OF COMMERCE 

Patent and Trademark Office 

[Docket No. PTO–P–2014–0067] 

Grant of Interim Extension of the Term 

of U.S. Patent No. 5,496,801; 

Recombinant Human Parathyroid 

Hormone 

AGENCY: United States Patent and 

Trademark Office, Commerce. 

ACTION: Notice of interim patent term 

extension. 

SUMMARY: The United States Patent and 

Trademark Office has issued an order 

granting interim extension under 35 

U.S.C. 156(d)(5) for a second one-year 

interim extension of the term of U.S. 

Patent No. 5,496,801. 

FOR FURTHER INFORMATION CONTACT: 

Mary C. Till by telephone at (571) 272– 

7755; by mail marked to her attention 

and addressed to the Commissioner for 

Patents, Mail Stop Hatch-Waxman PTE, 

P.O. Box 1450, Alexandria, VA 22313– 

1450; by fax marked to her attention at 

(571) 273–7755; or by email to 

Mary.Till@uspto.gov. 

SUPPLEMENTARY INFORMATION: Section 

156 of Title 35, United States Code, 

generally provides that the term of a 

patent may be extended for a period of 

up to five years if the patent claims a 

product, or a method of making or using 

a product, that has been subject to 

certain defined regulatory review, and 

that the patent may be extended for 

interim periods of up to one year if the 

regulatory review is anticipated to 

extend beyond the expiration date of the 

patent. 

On October 29, 2014, NPS 

Pharmaceuticals, Inc., timely filed an 

application under 35 U.S.C. 156(d)(5) 

for a second interim extension of the 

term of U.S. Patent No. 5,496,801. The 

patent claims the human biological 

product recombinant human 

parathyroid hormone. The application 

indicates that Biologics License 

Application 125511 for the drug 

product, recombinant human 

parathyroid hormone, was filed on 

October 24, 2013, and is currently 

undergoing regulatory review before the 

Food and Drug Administration for 

permission to market or use the product 

commercially. 

Review of the application indicates 

that, except for permission to market or 

use the product commercially, the 

subject patent would be eligible for an 

extension of the patent term under 35 

U.S.C. 156, and that the patent should 

be extended for one year as required by 

35 U.S.C. 156(d)(5)(B). Because the 

regulatory review period will continue 

beyond the extended expiration date of 

the patent, December 23, 2014, interim 

extension of the patent term under 35 

U.S.C. 156(d)(5) is appropriate. 

An interim extension under 35 U.S.C. 

156(d)(5) of the term of U.S. Patent No. 

5,496,801 is granted for a period of one 

year from the extended expiration date 

of the patent. 

mstockstill on DSK4VPTVN1PROD with NOTICES

73280 Federal Register / Vol. 79, No. 237 / Wednesday, December 10, 2014 / Notices 

Dated: December 5, 2014. 

Andrew Hirshfeld, 

Deputy Commissioner for Patent Examination 

Policy, United States Patent and Trademark 

Office. 

[FR Doc. 2014–28951 Filed 12–9–14; 8:45 am] 

BILLING CODE 3510–16–P 

CORPORATION FOR NATIONAL AND 

COMMUNITY SERVICE 

Revision of Information Collection; 

Comment Request 

AGENCY: Corporation for National and 

Community Service. 

ACTION: Notice. 

SUMMARY: The Corporation for National 

and Community Service (CNCS), as part 

of its continuing effort to reduce 

paperwork and respondent burden, 

conducts a pre-clearance consultation 

program to provide the general public 

and federal agencies with an 

opportunity to comment on proposed 

and/or continuing collections of 

information in accordance with the 

Paperwork Reduction Act of 1995 

(PRA95) (44 U.S.C. 3506(c)(2)(A)). This 

program helps to ensure that requested 

data can be provided in the desired 

format, reporting burden (time and 

financial resources) is minimized, 

collection instruments are clearly 

understood, and the impact of collection 

requirement on respondents can be 

properly assessed. 

Currently, CNCS is soliciting 

comments concerning proposed revision 

of its Senior Corps Grant Application 

(424–NSSC) (OMB Control Number 

3045–0035). The Grant Application is 

used by the Foster Grandparent, Senior 

Companion, and RSVP programs. CNCS 

proposes the following modifications to 

increase both the flexibility and the 

utility of the Senior Corps Grant 

Application so that it can serve as the 

source instructional document for data 

fields required to complete and submit 

an application for funding. Currently, 

the Grant Application contains two 

types of information needed by 

applicants: Instructional or ‘‘how-to’’ 

information and narrative questions and 

other content. While the instructions 

rarely change from year to year, the 

narrative questions and performance 

measures content can and do change 

annually, resulting in an ongoing need 

for Grant Application revisions for the 

upcoming year or competition. With 

this proposed change, CNCS will use 

the Senior Corps Grant Application 

exclusively to define data fields and 

describe how to enter the required data 

and information in each field. The Grant 

Application will not contain the content 

questions. The proposed change will be 

achieved by: (1) Removing and 

relocating narrative questions and other 

content materials from the Grant 

Application to applicable competitive 

Notices of Funding Opportunity and/or 

non-competitive Notices of Invitation to 

Apply for grant funds; (2) Removing 

performance measures requirements 

from the Grant Application and 

referring applicants to the OMB 

approved Performance Measures 

Requirements documents for the Senior 

Corps programs; and (3) replacing all 

existing Grant Application instructions 

with step-by-step eGrants instructions 

correlated to the Grant Application 

screens in eGrants. 

With these changes, applicants for 

Senior Corps grants can use a set of 

interrelated and readily available 

documents to complete the Grant 

Application. 

The proposed revisions do not change 

the estimated respondent burden. 

The proposed revisions do not change 

the data fields or data collected with the 

Senior Corps Grant Application. 

Copies of the information collection 

request can be obtained by contacting 

the office listed in the addresses section 

of this Notice. 

DATES: Written comments must be 

submitted to the individual and office 

listed in the ADDRESSES section by 

February 9, 2015. 

ADDRESSES: You may submit comments, 

identified by the title of the information 

collection activity, by any of the 

following methods: 

(1) By mail sent to: Corporation for 

National and Community Service, 

Senior Corps, Attention: Ms. Angela 

Roberts, Associate Director, 9401; 1201 

New York Avenue NW., Washington, 

DC 20525. 

(2) By hand delivery or by courier to 

the CNCS mailroom at Room 8100 at the 

mail address given in paragraph (1) 

above, between 9:00 a.m. and 4:00 p.m. 

Monday through Friday, except Federal 

holidays. 

(3) By fax to: (202) 606–3475, 

Attention: Ms. Angela Roberts, 

Associate Director. 

(4) Electronically through 

www.regulations.gov. Individuals who 

use a telecommunications device for the 

deaf (TTY–TDD) may call (202) 606– 

3472 between 8:30 a.m. and 5:00 p.m. 

Eastern Time, Monday through Friday. 

FOR FURTHER INFORMATION CONTACT: 

Angela Roberts by email at 

aroberts@cns.gov. 

SUPPLEMENTARY INFORMATION: CNCS is 

particularly interested in comments 

that: 

• Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of CNCS, including whether 

the information will have practical 

utility; 

• Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

• Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

• Minimize the burden of the 

collection of information on those who 

are expected to respond, including the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology 

(e.g., permitting electronic submissions 

of responses). 

Background 

The Senior Corps Grant Application is 

completed by applicant organizations 

interested in sponsoring a Senior Corps 

program. The grant application is also 

used by existing grantees to apply for 

continuation year grants (annual 

submissions in years two and three of a 

three year grant). The grant application 

is completed electronically using the 

CNCS web-based grants management 

system, eGrants. 

Current Action 

CNCS seeks to revise the current 

application with modifications. The 

proposed revisions do not change the 

estimated respondent burden. The 

information collection will otherwise be 

used for the same purpose as the 

existing application. CNCS also seeks to 

continue using the current application 

until the revised application is 

approved by OMB. The current 

application is due to expire on 

September 30, 2015. 

Type of Review: Revision. 

Agency: Corporation for National and 

Community Service. 

Title: National Senior Service Corps 

Grant Application. 

OMB Number: 3045–0035. 

Agency Number: SF 424–NSSC. 

Affected Public: Current and 

prospective sponsors of National Senior 

Service Corps Grants. 

Total Respondents: 1,350. 

Frequency: Annually, with 

exceptions. 

Average Time per Response: 

Estimated at 13.2 hours each. 

Estimated Total Burden Hours: 17,820 

hours. 

Total Burden Cost (capital/startup): 

None. 

mstockstill on DSK4VPTVN1PROD with NOTICES